NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain.
NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain.
Cytokine Growth Factor Rev. 2022 Dec;68:25-36. doi: 10.1016/j.cytogfr.2022.07.002. Epub 2022 Jul 6.
Considering the high impact that severe Coronavirus disease 2019 (COVID-19) cases still pose on public health and their complex pharmacological management, the search for new therapeutic alternatives is essential. Mesenchymal stromal cells (MSCs) could be promising candidates as they present important immunomodulatory and anti-inflammatory properties that can combat the acute severe respiratory distress syndrome (ARDS) and the cytokine storm occurring in COVID-19, two processes that are mainly driven by an immunological misbalance. In this review, we provide a comprehensive overview of the intricate inflammatory process derived from the immune dysregulation that occurs in COVID-19, discussing the potential that the cytokines and growth factors that constitute the MSC-derived secretome present to treat the disease. Moreover, we revise the latest clinical progress made in the field, discussing the most important findings of the clinical trials conducted to date, which follow 2 different approaches: MSC-based cell therapy or the administration of the secretome by itself, as a cell-free therapy.
考虑到严重的 2019 年冠状病毒病（COVID-19）病例仍然对公共卫生造成的巨大影响及其复杂的药理学管理，寻找新的治疗方法至关重要。间充质基质细胞（MSCs）可能是很有前途的候选者，因为它们具有重要的免疫调节和抗炎特性，可以对抗 COVID-19 中发生的急性严重呼吸窘迫综合征（ARDS）和细胞因子风暴，这两个过程主要是由免疫失衡驱动的。在这篇综述中，我们全面概述了 COVID-19 中发生的免疫失调引起的复杂炎症过程，讨论了构成 MSC 来源的分泌组的细胞因子和生长因子在治疗该疾病方面的潜力。此外，我们还回顾了该领域的最新临床进展，讨论了迄今为止进行的临床试验的最重要发现，这些临床试验采用了两种不同的方法：基于 MSC 的细胞治疗或单独给予分泌组作为无细胞治疗。
